Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;41(2):136-149.
doi: 10.23876/j.krcp.22.001. Epub 2022 Mar 25.

GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions

Ji Hee Yu  1 , So Young Park  1 , Da Young Lee  1 , Nan Hee Kim  1 , Ji A Seo  1
Affiliations

GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions

Ji Hee Yu et al. Kidney Res Clin Pract. 2022 Mar.

Abstract

With the emergence of various classes of blood glucose-lowering agents, choosing the appropriate drug for each patient is emphasized in diabetes management. Among incretin-based drugs, glucagon-like peptide 1 (GLP-1) receptor agonists are a promising therapeutic option for patients with diabetic kidney disease (DKD). Several cardiovascular outcome trials have demonstrated that GLP-1 receptor agonists have beneficial effects on cardiorenal outcomes beyond their blood glucose-lowering effects in patients with type 2 diabetes mellitus (T2DM). The renal protective effects of GLP-1 receptor agonists likely result from their direct actions on the kidney, in addition to their indirect actions that improve conventional risk factors for DKD, such as reducing blood glucose levels, blood pressure, and body weight. Inhibition of oxidative stress and inflammation and induction of natriuresis are major renoprotective mechanisms of GLP-1 analogues. Early evidence from the development of dual and triple combination agents suggests that GLP-1 receptor agonists will probably become popular treatment options for patients with T2DM.

Keywords: Diabetic nephropathies; Glucagon-like peptide 1; Type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

All authors have no conflicts of interest to declare.

Figures

Figure 1.
Figure 1.. The mechanisms underlying the nephroprotective effects of GLP-1 receptor agonists.
GLP-1, glucagon-like peptide 1.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12:2032–2045. - PMC - PubMed
    1. Jung CH, Son JW, Kang S, et al. Diabetes fact sheets in Korea, 2020: an appraisal of current status. Diabetes Metab J. 2021;45:1–10. - PMC - PubMed
    1. Baik I. Projection of diabetes prevalence in Korean adults for the year 2030 using risk factors identified from national data. Diabetes Metab J. 2019;43:90–96. - PMC - PubMed
    1. Hong YA, Ban TH, Kang CY, et al. Trends in epidemiologic characteristics of end-stage renal disease from 2019 Korean Renal Data System (KORDS) Kidney Res Clin Pract. 2021;40:52–61. - PMC - PubMed
    1. Jin DC, Han JS. Renal replacement therapy in Korea, 2012. Kidney Res Clin Pract. 2014;33:9–18. - PMC - PubMed

LinkOut - more resources

  NODES
INTERN 2
Project 1
twitter 2